Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 235

The DOI matches its Crossref record.

Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation

Open access
Hachem, Ramsey R., Yusen, Roger D., Meyers, Bryan F., Aloush, Aviva A., Mohanakumar, Thalachallour, Patterson, G. Alexander, Trulock, Elbert P. · 2010 · The Journal of Heart and Lung Transplantation

Abstract

Background Because the development of donor-specific anti-HLA antibodies (DSA) after lung transplantation has been associated with acute and chronic rejection we implemented a clinical protocol to screen all recipients for DSA after transplantation and preemptively treat those who develop DSA with rituximab and intravenous immune globulin (IVIG) or IVIG alone. Methods We conducted a prospective observational study of this protocol and used the LABScreen® Single Antigen assay to detect DSA after transplantation. We compared the incidence of acute rejection, lymphocytic bronchiolitis, and bronchiolitis obliterans syndrome (BOS) between those who developed DSA and those who did not using Cox proportional hazards models and compared freedom from BOS and survival between those who had persistent DSA and those who had successful depletion of DSA using the Kaplan-Meier method. Results Among 116 recipients screened, 65 developed DSA during the study period. Those who developed DSA and received antibody-directed therapy had a similar incidence of acute rejection, lymphocytic bronchiolitis, and BOS as those who did not develop DSA. Furthermore, recipients who had successful depletion of DSA had greater freedom from BOS and better survival than those who had persistent DSA. Finally, those treated for DSA had a similar incidence of infectious complications as those who did not develop DSA. Conclusions The development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2010.05.006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 235

Metadata

Authors
Hachem, R. R., Yusen, R. D., Meyers, B. F., Aloush, A. A., Mohanakumar, T., Patterson, G. A., & Trulock, E. P.
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2010-09
Volume
29
Issue
9
Pages
973-980
ISSN
1053-2498 (ISSN-L)
OpenAlex
W2075033611
Cited by
235
References
0
FWCI
16.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. https://app.cochat.ai/papers/10.1016/j.healun.2010.05.006
The paper
Hachem, R. R., Yusen, R. D., Meyers, B. F., Aloush, A. A., Mohanakumar, T., Patterson, G. A., & Trulock, E. P. (2010). Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2010.05.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.